Richard Stone - DarioHealth Corp Independent Director
DRIO Stock | USD 1.50 0.05 3.45% |
Director
Prof. Richard B. Stone is Independent Director of the Company, effective July 7, 2014. For more than twentyfive years, Mr. Stone was active participant in early stage business enterprises as a director or investor, including technology and biotechnology companies. He currently serves on the board of directors of multiple technology companies, including Powermat, EsproAccoustiguide Group, Wellsense Technologies, NanoX Imaging Plc, Illumigyn Ltd, Cardiologic Innovations, Quality Inflow Ltd., and CheckCap. Since 1974, Mr. Stone was a member of the faculty of Columbia Law School, where he held the Wilbur Friedman Chair in Tax Law for twenty years. In addition to basic and advanced tax courses, Mr. Stone has taught in the areas of contracts, business planning and real estate planning. Among other notforprofit organizations he was associated with, from 2011 to 2013, Mr. Stone served as Chairman of the Conference of Presidents of Major American Jewish Organizations. Mr. Stone began his career in 1967 in private practice in Washington, D.C., and thereafter joined the staff of the Solicitor General of the United States, where from 1969 to 1973 he was Assistant to the Solicitor General. He is a graduate of Harvard College and Harvard Law School. We believe Mr. Stone is qualified to serve on our Board because of his legal expertise and experience with life sciences companies. since 2014.
Age | 64 |
Tenure | 10 years |
Address | 322 West 57th St., New York, NY, United States, 10011 |
Phone | 972 477 0637 7 |
Web | https://www.dariohealth.com |
DarioHealth Corp Management Efficiency
The company has return on total asset (ROA) of (0.3251) % which means that it has lost $0.3251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8604) %, meaning that it created substantial loss on money invested by shareholders. DarioHealth Corp's management efficiency ratios could be used to measure how well DarioHealth Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -1.17. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, DarioHealth Corp's Debt To Assets are very stable compared to the past year. As of the 25th of April 2024, Asset Turnover is likely to grow to 0.36, though Non Currrent Assets Other are likely to grow to (4.8 M).Similar Executives
Found 11 records | DIRECTOR Age | ||
Mary Tagliaferri | Enzo Biochem | 53 | |
MS MD | Sera Prognostics | 71 | |
Michael Byron | Burning Rock BiotechLtd | 55 | |
Gregory Bortz | Enzo Biochem | 48 | |
Dieter Schapfel | Enzo Biochem | 57 | |
Bernard Kasten | Enzo Biochem | 68 | |
Bruce Hanna | Enzo Biochem | 75 | |
Brian Gavin | Burning Rock BiotechLtd | N/A | |
Tina Nova | Exagen Inc | 70 | |
Ian Walters | Enzo Biochem | 52 | |
Dov Perlysky | Enzo Biochem | 58 |
Management Performance
Return On Equity | -0.86 | ||||
Return On Asset | -0.33 |
DarioHealth Corp Leadership Team
Elected by the shareholders, the DarioHealth Corp's board of directors comprises two types of representatives: DarioHealth Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DarioHealth. The board's role is to monitor DarioHealth Corp's management team and ensure that shareholders' interests are well served. DarioHealth Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DarioHealth Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Zvi CPA, Treasurer CFO | ||
Glen Moller, Director | ||
Josh Fischer, Senior Compliance | ||
Dov Oppenheim, CoFounder Chief | ||
Rami Yehudiha, Director | ||
Hila Karah, Director | ||
Richard Anderson, President | ||
Claudia Levi, Content Manager | ||
Jean Muyl, Head America | ||
Zvi David, Treasurer CFO | ||
Yalon Farhi, Director | ||
Erez Raphael, Chairman, CEO and Pres | ||
Ori Zanco, Director | ||
Mary Mooney, Vice Marketing | ||
Limor Drezner, Chief Officer | ||
Dennis McGrath, Director | ||
Olivier Jarry, President and Chief Commercial Officer | ||
Malcolm Hoenlein, Independent Director | ||
Richard Stone, Independent Director | ||
Tomer BenKiki, Chief Officer | ||
Brian Harrigan, Senior Sales | ||
Yossi Bahagon, Director | ||
Yoav Shaked, Chairman of the Board | ||
Dror Bacher, Chief Officer | ||
Zvi BenDavid, CFO, Treasurer, Secretary | ||
Allen Kamer, Director | ||
Omar MD, Chief Officer |
DarioHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DarioHealth Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.86 | ||||
Return On Asset | -0.33 | ||||
Profit Margin | (2.92) % | ||||
Operating Margin | (3.90) % | ||||
Current Valuation | 31.61 M | ||||
Shares Outstanding | 29.44 M | ||||
Shares Owned By Insiders | 14.81 % | ||||
Shares Owned By Institutions | 29.43 % | ||||
Number Of Shares Shorted | 1.36 M | ||||
Price To Earning | (2.30) X |
Pair Trading with DarioHealth Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DarioHealth Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DarioHealth Corp will appreciate offsetting losses from the drop in the long position's value.Moving against DarioHealth Stock
0.77 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.75 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.74 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
0.69 | NXL | Nexalin Technology | PairCorr |
0.63 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
The ability to find closely correlated positions to DarioHealth Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DarioHealth Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DarioHealth Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DarioHealth Corp to buy it.
The correlation of DarioHealth Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DarioHealth Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DarioHealth Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DarioHealth Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DarioHealth Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in DarioHealth Stock, please use our How to Invest in DarioHealth Corp guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for DarioHealth Stock analysis
When running DarioHealth Corp's price analysis, check to measure DarioHealth Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DarioHealth Corp is operating at the current time. Most of DarioHealth Corp's value examination focuses on studying past and present price action to predict the probability of DarioHealth Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DarioHealth Corp's price. Additionally, you may evaluate how the addition of DarioHealth Corp to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is DarioHealth Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DarioHealth Corp. If investors know DarioHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DarioHealth Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share 0.717 | Quarterly Revenue Growth (0.47) | Return On Assets (0.33) | Return On Equity (0.86) |
The market value of DarioHealth Corp is measured differently than its book value, which is the value of DarioHealth that is recorded on the company's balance sheet. Investors also form their own opinion of DarioHealth Corp's value that differs from its market value or its book value, called intrinsic value, which is DarioHealth Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DarioHealth Corp's market value can be influenced by many factors that don't directly affect DarioHealth Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DarioHealth Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if DarioHealth Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DarioHealth Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.